Exploring the Association Between Phthalates Exposure, Measured Through Their Urinary Metabolites, and Renal Function Impairment in Individuals With TYpe 2 Diabetes - SGLT2 Subprotocol
试验速览
- 阶段
- 4 期
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Urinary Phthalates concentration
研究概览
简要总结
In this open clinical trial, 30 subjects with inadequately controlled T2D and eligible, as per good clinical practice, for therapy with SGLT-2 inhibitor, will be randomized to receive a SGLT-2 inhibitor vs other oral-antidiabetic drugs (OADs) therapy for 3 months. Measures will be performed at baseline, after 2 days, after one month and at the end of the study protocol, as per good clinical practice
详细描述
- Total concentrations of MEHP, MEOHP and MEHHP will be quantified, in the laboratories of the Institute of Clinical Physiology, National Research Council, Pisa, in a spot morning urine sample by ultra-HPLC coupled with electrospray ionization/quadrupole time-of-flight mass spectrometry (Agilent UHPLC 1290 infinity coupled to an Agilent 6540 MS-QTOF, Santa Clara, CA) using stable isotope labeled substrates, i.e. MEHP (ring-1,2-13C2, dicarboxyl-13C2), MEHHP, MEHHP 13C4, MEOHP and MEOHP 13C4 that will be purchased from Cambridge Isotope Laboratories (Tewksbury, MA).
- Urinary creatinine concentrations will be measured to adjust urinary concentrations of DEHP metabolite (Beckman Coulter AU400, Brea, CA), thus minimizing the influence of urine volume.
- Serum and urinary inflammatory markers and adipocytokines will be quantitatively determined using sandwich enzyme-linked immunosorbent assays kits according to the manufacturer's instructions. Optical density will be measured using a microplate reader.
- Serum and urinary markers of oxidative stress will be measured by gold standard techniques. In detail, MDA will be quantified by TBARS reactive substances measured by optical density; GSH-Px by a specific assay kit according to the manufacturer's instruction; SOD activity will be determined using a specific SOD kit; urinary 8-isoprostane concentration will be measured by a specific affinity sorbent. (Cayman Chemical, Ann Harbor, MI, USA) according to the manufacturer's instructions.
- To analyze mitochondrial DNA we will apply a triplex design previously reported to amplify mitochondria loci located within the MinorArc and MajorArc, respectively. To assess nuclear DNA, we will use RNase P Copy Number Reference.
- The phthalates-free diet will be self-administered by the individuals under intervention, following a set of instruction and rules provided by the physicians based on the current literature data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individuals of both sex;
- •Age between 18 and 85 years;
- •T2D duration > 6 months
- •BMI ≤ 40 Kg/m2,
- •HbA1c > 48 mmol/mol
- •Eligible for SGLT-2i therapy
- •Exclusion criteria
- •age >85 years,
- •eGFR <60 ml/min/1.73 m2,
- •occurring acute complications
排除标准
- 未提供
研究组 & 干预措施
Dapaglifozin
People undergoing SGLT2i (Dapaglifozin) therapy
干预措施: Dapagliflozin 10 MG (Drug)
Hydrochlorothiazide
People undergoing thiazide (Hydrochlorothiazide) therapy
干预措施: Hydrochlorothiazide 12.5mg (Drug)
结局指标
主要结局
Urinary Phthalates concentration
时间窗: Changes between baseline and 3 month
Exposure to phthalates assessed through urinary excretion spot and 24-hours
次要结局
- Renal function(1 and 3 months)
- Glycated Haemoglobin(1 and 3 months)
- Albumin excretion(1 and 3 months)
- Macrovascular events(1 and 3 months)
- Fasting glucose(1 and 3 months)
研究者
Anna Solini
Associate Professor
University of Pisa
